Condition: Healthy Aging and Parkinson's Disease · Sponsor: Hospices Civils de Lyon
The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (here Parkinson's disease) through the use of a newly developed radiotracer visualizing alpha2C-ARs (\[11C\]ORM-13070) combined with a cutting-edge technology, the hybrid PET/MRI scanner. The secondary aim will be to determine whether the expected age- and PD-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (i.e. cognitive, motor and/or olfactory abilities).
This description comes directly from the study's public registry record.
Chloé Laurencin, MD / PhD · 472118022 · chloe.laurencin@chu-lyon.fr
Bénédicte Ballanger, PhD · 472138978 · benedicte.ballanger@cnrs.fr
Always discuss trial participation with your own doctor first.
| Hôpital Neurologique Pierre Wertheimer - Service de Neurologie | Bron, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07569120